Methods for screening tumors for p53 status and therapeutic exploitation

Expert Review of Molecular Diagnostics

Volumn 3, Issue 3, 2003, Pages 289-301

  Tullo, Apollonia ^a   D'Erchia, Anna Maria ^b   Sbisa, Elisabetta ^a  

^a CNR   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Gene therapy; Microarray; Molecular diagnosis; Mutation detection; p53; Sequencing; Small peptides

Indexed keywords

ARF PROTEIN; DNA; ONYX 015; PROTEIN MDM2; PROTEIN P53;

ANALYTIC METHOD; CANCER CYTODIAGNOSIS; CANCER SCREENING; DIAGNOSTIC VALUE; DRUG EFFICACY; EVALUATION; GENE MUTATION; GENE THERAPY; GENETIC SCREENING; HUMAN; ONCOGENE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; GENE THERAPY; GENES, P53; GENETIC SCREENING; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038286378     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.3.3.289     Document Type: Review

References (80)

1. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 10, 1054-1072 (1996).
2. Hansen R, Oren M. p53: from inductive signal to cellular effect. Curr. Opin. Genet. Dev. 7, 46-51 (1997).
3. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 88(3), 323-331 (1997).
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network Nature 408, 307-310 (2000).
5. Sharpless NE, De Pinho RA. p53: good cop/bad cop. Cell 110, 9-12 (2002).
6. D'Erchia AM, Tullo A, Pesole G, Saccone C, Sbisà E. p53 gene family: structural, functional and evolutionary features. Curr. Genomics 4, 13-26 (2003).
7. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN. Phoshorilation of p53 serine 15 increases interaction with CBP J. Biol. Chem. 273, 33048-33053 (1998).
8. Hupp TR. Regulation of p53 protein function through alterations in protein-folding pathways. Cell Mol. Life Sci. 55(1), 88-95 (1999).
9. Gostissa M, Hengstermann A, Fogal V et al. Activation of p53 by conjugation to the ubiquitin-like SUMO- 1. EMBO J. 18, 6462-6471 (1999).
10. Jayaraman L, Prives C. Covalent and noncovalent modifiers of the p53 protein. Cell Mol. Sci. 55, 76-87 (1999).
11. Kubbutat MHG, Vousden KH. Keeping an old friend under control: regulation of p53 stability. Mol. Med. Today 4, 250-256 (1998).
12. Lohrum MAE, Vousden KH. Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol. 10, 197-202 (2000).
13. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12, 2984-2991 (1998).
14. Tyner SD, Venkatachalam S, Choi J et al. p53 mutant mice that display early aging-associated phenotypes. Nature 415 (6867), 45-53 (2002).
15. Tullo A, Sbisà E. Molecular characterization of p53 mutations in primary and secondary liver tumors: diagnostic and therapeutic perspectives. Mol. Biotechnol. 21(3), 265-278 (2002).
16. Storey A, Thomas M, Kalita A et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393(6682), 229-234 (1998).
17. Marin MC, Jost CA, Brooks LA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nature Genet. 25(1), 47-54 (2000).
18. Bullock A, Henckel J, Fersht A. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19(10),1245-1256 (2000).
19. Hupp TR, Meek DW, Midgley CA, Lane DP. Activation of the cryptic DNA binding function of mutant form of p53. Nucleic Acids Res. 21(14), 3167-3174 (1993).
20. Lomax ME, Barnes DM, Hupp TR, Picksley SM, Camplejohn RS. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni-like family members. Oncogene 17, 643-649 (1998).
21. Thomas M, Pim D, Banks L The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18(53), 7690-7700 (1999).
22. Wallace-Brodeur RR, Lowe SW. Clinical implication of p53 mutations. Cell Mol. Life Sci. 54, 64-75 (1999). Review provides an extensive insight into the biology of p53 and the strategies to exploit p53 for cancer diagnosis and therapy.
23. Sherr CJ. The INK4a/ARF network in tumor suppression. Nat. Rev. Mol. Cell Biol. 2, 731-737 (2001).
24. Rampino N, Yamamoto H, Ionov Y et al. Somatic frameshift mutations in the Bax gene in colon cancers of the microsatellite mutator phenotype. Science 275, 967-969 (1997).
25. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl Acad. Sci. USA 94, 2345-2349. (1997).
26. Bunz F, Hwang PM, Torrance C et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104(3), 223-225 (1999).
27. Negm RS, Verma M, Srivastava S. The promise of biomarkers in cancer screening and detection. Trends Mol. Med. 8(6), 288-293 (2002).
28. Sidransky D, Von Eschenbach A, Tsai YC et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252(5006), 706-709 (1991).
29. Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 54(7), 1634-1637 (1994).
30. Lubin R, Zalcman G, Bouchet L et al. Serum p53 antibodies as early markers of lung cancer. Nat. Med. 1(7), 701-702 (1995).
31. Zalcman G, Tredaniel J, Schlichtholz B et al. Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. Int. J. Cancer. 89(1), 81-86 (2000).
32. Baas IO, van den Berg FM, Mulder JW et al. Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J. Pathol. 178(3), 264-267 (1996).
33. Kang YK, Kim WH, Lee HW, Lee HK, Kim YI. Mutation of p53 and K-ras and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab. Invest. 79(4), 477-483 (1999).
34. Duddy PM, Hanby AM, Barnes DM, Camplejohn RS. Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay J. Mol. Diagn. (3), 139-144 (2000).
35. Mashal RD, Sklar J. Practical methods of mutation detection. Curr. Opin. Genet. Dev. 6(3), 275-280 (1996).
36. Whitcombe D, Newton CR, Little S. Advances in approaches to DNA-based diagnostics. Curr Opin. Biotechnol. 9(6), 602-608 (1998). Review describing the principles of the most used methodologies and the emerging technologies which meet the increasing demand for mutation detection in the clinical setting.
37. Hodgson DR, Foy CA, Partridge M, Pateromichelakis S, Gibson NJ. Development of a facile fluorescent assay for the detection of 80 mutations within the p53 gene. Mol. Med. 8(5), 227-237 (2002).
38. Kaur M, Zhang Y, Liu WH, Tetradis S, Price BD, Makrigiorgos GM. Ligation of a primer at a mutation: a method to detect low level mutations in DNA. Mutagenesis 17(5), 365-374 (2002).
39. Zhang Y, Kaur M, Price BD, Tetradis S, Makrigiorgos GM. An amplification and ligation-based method to scan for unknown mutations in DNA. Hum. Mutat. 20(2), 139-147 (2002).
40. Huang J, Kirk B, Favis R et al. An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue. Oncogene 21(12), 1909-1921 (2002).
41. Chakrabarti S, Price BD, Tetradis S et al. Highly selective isolation of unknown mutations in diverse DNA fragments: toward new multiplex screening in cancer. Cancer Res. 60(14), 3732-3737 (2000).
42. Bosserhoff AK Buettner R, Hellerbrand C. Use of capillary electrophoresis for high-throughput screening in biomedical applications. A minireview. Comb. Chem. High Throughput Screen. 3(6), 455-466 (2000).
43. Gelfi C, Vigano A, Palma SD et al. Single-strand conformation polymorphism for p53 mutation by a combination of neutral pH buffer and temperature gradient in capillary electrophoresis. Electrophoresis 23(10), 1517-1523 (2002).
44. Siles BA, O'Neil KA, Tung DL Bazar L, Collier GB, Lovelace CI. The use of dynamic size-sieving capillary electrophoresis and mismatch repair enzymes for mutant DNA analysis. J. Capillary Electrophor. 5 (1-2), 51-58 (1998).
45. Bjorheim J, Gaudemack G, Ekstrom PO. Mutation analysis of TP53 exons 5-8 by automated constant denaturant capillary electrophoresis. Tumour Biol. 22(5), 323-327 (2001).
46. Kourkine IV, Hestekin CN, Buchholz BA, Barron AE. High-throughput, high-sensitivity genetic mutation detection by tandem single-strand conformation polymorphism/heteroduplex analysis capillary array electrophoresis. Anal. Chem. 74(11), 2565-2572 (2002).
47. Garcia CA, Ahmadian A, Gharizadeh B, Lundeberg J, Ronaghi M, Nyren P. Mutation detection by pyrosequencing: sequencing of exons 5-8 of the p53 tumor suppressor gene. Gene 253(2), 249-257 (2000).
48. Schmalzing D, Belenky A, Novotny MA et al. Microchip electrophoresis: a method for high-speed SNP detection. Nucleic Acids Res. 28(9), E43 (2000).
49. Behrensdorf HA, Pignot M, Windhab N, Kappel A. Rapid parallel mutation scanning of gene fragments using a microelectronic protein-DNA chip format. Nucleic Acids Res. 30(14), e64 (2002).
50. Takahashi Y, Nagata T, Asai S et al. Detection of aberrations of 17p and p53 gene in gastrointestinal cancers by dual (two-color) fluorescence in situ hybridization and GeneChip p53 assay. Cancer Genet. Cytogenet. 121(1), 38-43 (2000).
51. Ahrendt SA, Halachmi S, Chow JT et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc. Natl Acad. Sci. USA 96(13), 7382-7387 (1999).
52. Shumaker JM, Tollet JJ, Filbin KJ, Montague-Smith MP, Pirrung MC. APEX disease gene resequencing: mutations in exon 7 of the p53 tumor suppressor gene. Bioorg. Med. Chem. 9(9), 2269-2278 (2001).
53. Tonisson N, Zernant J, Kurg A et al. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc. Natl Acad. Sci. USA 99(8), 5503-5508 (2002). Paper describing the development of an arrayed primer extension assay (APIEX) for the rapid and sensitive identification of p53 mutations.
54. Wen WH, Bernstein L, Lescallett J et al. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res. 60(10), 2716-2722 (2000). Paper reports the comparison between the p53 mutation detection by gel-based DNA sequence and microarray (p53 GeneChip).
55. Wikman FP, Lu ML, Thykjaer T et al. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin. Chem. 46(10), 1555-1561 (2000).
56. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 (5286), 342-343 (1996). Paper reports the smart therapeutic strategy that uses a mutant human adenovirus that does not express the protein E1B and it can replicate in and lyse p53-deficient human tumor cells but not cells with functional p53.
57. Biederer C, Ries S, Brandts CH, McCormick E Replication-selective viruses for cancer therapy J. Mol. Med. 80(3), 163-175 (2002).
58. Cohen EE, Rudin CM, ONYX.-015. Onyx Pharmaceuticals. Curr. Opin. Investig. Drugs 2(12), 1770-1775 (2001).
59. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 9(12), 979-986 (2002).
60. Zhu J, Gao B, Zhao J, Balmain A. Targeting gene expression to tumor cells with loss of wild type p53 function. Cancer Gene Ther. 7(1), 4-12 (2000).
61. Boulikas T. Cancer gene therapy and immunotherapy. Int. J. Oncol. 9, 941-954 (1996).
62. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83, 237 (1995).
63. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 286(5449), 2507-2510 (1999).
64. Selivanova G, Iotsova V, Okan I et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3(6), 632-638 (1997).
65. Selivanova G, Ryabchenko L Jansson E, Iotsova V, Wiman KG. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol. Cell Biol. 19(5), 3395-3402 (1999).
66. Bykov VJ, Issaeva N, Shilov A et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8(3), 282-288 (2002).
67. Watanabe T, Sullenger BA. Induction of wild type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc. Natl Acad. Sci. USA 97(15), 8490-8494 (2000).
68. de Fromentel CC, Gruel N, Venot C et al. Restoration of transcriptional activity of p53 mutants in human tumor cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 18(2), 551-557 (1999).
69. Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med. 8(Suppl. 4), S32-S37 (2002).
70. Tzung SP, Kim KM, Basanez G et al. Antimycin A mimics a cell-death-inducing Bd-2 homology domain 3. Nat. Cell Biol. 3(2), 183-191 (2001).
71. Komarov PG, Komarova EA, Kondratov RV et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285(5434), 1733-1737 (1999).
72. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein Cell Mol. Life Sci. 55(1), 96-107 (1999).
73. Zhang, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr. Pharm. Des. 6(4), 393-416 (2000).
74. Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res. 7(11), 3613-3624 (2001).
75. Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 20(25), 3206-3216 (2001).
76. Bottger V, Bottger A, Howard SF et al. Identification of novel MDM2 binding peptides by phage display. Oncogene 13(10), 2141-2147 (1996).
77. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell Biol. 18(12), 7288-7293 (1998).
78. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 23(7), 1127-1130 (2002).
79. Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild type p53. Cancer Res. 61(16), 5959-5963 (2001).
80. Caspari T. How to activate p53. Curr. Biol. 10(8), R315-R317 (2000).